Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM1315MO2 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0000853 | uM | 10875.154 | 0.9970 | 0.9916 | 0.7163 | |
| SUM1315MO2 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000427 | uM | 10875.154 | 1.0247 | 1.0693 | 0.7163 | |
| SUM1315MO2 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00213 | uM | 10875.154 | 1.0172 | 1.0482 | 0.7163 | |
| SUM1315MO2 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 10875.154 | 0.9622 | 0.8953 | 0.7163 | |
| SUM1315MO2 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 10875.154 | 0.7066 | 0.2314 | 0.7163 | |
| SUM1315MO2 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 10875.154 | 0.4376 | -0.3692 | 0.7163 | |
| SUM1315MO2 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 10875.154 | 0.3209 | -0.5909 | 0.7163 | |
| SUM1315MO2 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 6.67 | uM | 10875.154 | 0.1952 | -0.7957 | 0.7163 | |
| SUM1315MO2 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 33.3 | uM | 10875.154 | 0.0111 | -0.9963 | 0.7163 | |
| SUM1315MO2 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0000853 | uM | 12428.167 | 0.9626 | 0.9265 | 1.0169 | |
| SUM1315MO2 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000427 | uM | 12428.167 | 0.9351 | 0.8722 | 1.0169 | |
| SUM1315MO2 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00213 | uM | 12428.167 | 0.9354 | 0.8728 | 1.0169 | |
| SUM1315MO2 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 12428.167 | 0.9653 | 0.9318 | 1.0169 | |
| SUM1315MO2 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 12428.167 | 0.7424 | 0.4921 | 1.0169 | |
| SUM1315MO2 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 12428.167 | 0.4696 | -0.0490 | 1.0169 | |
| SUM1315MO2 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 12428.167 | 0.3763 | -0.2352 | 1.0169 | |
| SUM1315MO2 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 6.67 | uM | 12428.167 | 0.2555 | -0.4773 | 1.0169 | |
| SUM1315MO2 | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 33.3 | uM | 12428.167 | 0.0109 | -0.9765 | 1.0169 | |
| SUM149PT | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0000853 | uM | 10819.154 | 1.0800 | 1.0758 | 2.0680 | |
| SUM149PT | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000427 | uM | 10819.154 | 0.8860 | 0.8863 | 2.0680 | |
| SUM149PT | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00213 | uM | 10819.154 | 1.0298 | 1.0286 | 2.0680 | |
| SUM149PT | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 10819.154 | 0.9280 | 0.9290 | 2.0680 | |
| SUM149PT | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 10819.154 | 0.7311 | 0.7189 | 2.0680 | |
| SUM149PT | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 10819.154 | 0.5275 | 0.4679 | 2.0680 | |
| SUM149PT | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 10819.154 | 0.1686 | -0.1544 | 2.0680 |